PANCREATIC CANCER ACTION NETWORK

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1999-01-01

Employees: -

Market Cap: -

Website: https://www.pancan.org/

Clinical Trials

Active:1

Completed:2

Trial Phases

3 Phases

Phase 1:1

Phase 3:1

Not Applicable:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable

1 (33.3%)

Phase 1

1 (33.3%)

Phase 3

1 (33.3%)

Early Detection Initiative for Pancreatic Cancer

Not Applicable

Active, not recruiting

Conditions: Hyperglycemia
Diabetes Mellitus
Pancreas Ductal Adenocarcinoma

First Posted Date: 2020-12-10

Last Posted Date: 2025-06-08

Lead Sponsor: Pancreatic Cancer Action Network

Target Recruit Count: 8869

Registration Number: NCT04662879

Locations: 🇺🇸
Kaiser Permanente Southern California, Kaiser Permanente Research, Pasadena, California, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

Phase 1

Completed

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine

First Posted Date: 2020-10-09

Last Posted Date: 2025-05-04

Lead Sponsor: Pancreatic Cancer Action Network

Target Recruit Count: 10

Registration Number: NCT04581343

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
New York University, New York, New York, United States

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine combined with nab-paclitaxel
Drug: Dose -mFOLFIRINOX
Drug: Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
Drug: Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine

First Posted Date: 2020-01-14

Last Posted Date: 2025-04-06

Lead Sponsor: Pancreatic Cancer Action Network

Target Recruit Count: 502

Registration Number: NCT04229004

Locations: 🇺🇸
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

and more 22 locations

News

Oncolytics' Pelareorep Shows Promise in Pancreatic Cancer Trial, GOBLET Cohort 5 Enrollment Continues

7 months ago

The Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study, which is evaluating pelareorep in pancreatic cancer.